cadrg-tacpad (Agenda)

Agenda 

All times are in EST.

Day 1 - Monday, September 13

Welcome Remarks
10:00-10:15 AM Mark Miller, Ph.D.
Program Director, Chemopreventive Agent Development Research Group
Division of Cancer Prevention, NCI
Patient Advocates Forum*
10:15-11:00 AM

Overview of Session 1 Presentations: Early Discovery Research on Immunomodulatory Agents for Cancer Prevention

Session Chair: Lori Minasian, M.D.
Deputy Director
Division of Cancer Prevention, NCI

11:00-11:45 AM

Overview of Session 2 Presentations: Combinations of Immunomodulators with Cancer Preventive Agents or Vaccines

Session Chair: Margaret Wojtowicz, M.D.
Medical Officer and Program Director
Lung & Upper Aerodigestive Cancer Research Group
Division of Cancer Prevention, NCI

11:45 AM -12:30 PM

Overview of Session 3 Presentations: Immune Checkpoint Inhibitors in Immunointerception or immunoprevention

Session Chair: Asad Umar, D.V.M., Ph.D.
Chief
Gastrointestinal and Other Cancers Research Group
Division of Cancer Prevention, NCI

12:30-1:15 PM BREAK
Introduction to the Scientific Sessions
1:15-1:45 PM

Survey of Mechanistic Classes of Immunomodulatory Agents

Robert Shoemaker, Ph.D.
Chief
Group Chief, Chemopreventive Agent Development Research Group
Division of Cancer Prevention, NCI

Session 1**
Early Discovery Research on Immunomodulatory Agents for Cancer Prevention
Co-Chairs: Shizuko Sei, M.D. and Elizabeth Jaffe, M.D.
1:45-2:15 PM

Intercepting Pancreatic Cancer Development with Oncogene Targeted Immunotherapy

Elizabeth Jaffe, M.D.
Deputy Director, The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University

2:15-2:45 PM

Immune-Modulation Interference in Early Oncogenesis Event

Samir Khleif, M.D.
Director of Jeannie and Tony Loop Immuno-Oncology Center,
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center

2:45-3:15 PM BREAK
3:15-3:45 PM

Epigenetic Modifiers for Immunomodulation

Roderick Dashwood, Ph.D.
Director of the Center for Epigenetics & Disease Prevention
Texas A&M Health Science Center

3:45-4:15 PM

Topical Prevention of Skin Photocarcinogenesis: Targeting Toll-like Receptor 4 (TLR4) and Beyond

Georg Wondrak, Ph.D.
Professor, Pharmacology and Toxicology
University of Arizona Cancer Center

4:15-5:00 PM Discussion
5:00 PM ADJOURN
Altaf Mohammed, Ph.D.

 

 

Day 2 - Tuesday, September 14

Welcome Remarks
9:50-10:00 AM Mark Miller, Ph.D.
Program Director, Chemopreventive Agent Development Research Group
Division of Cancer Prevention, NCI
Session 2
Combinations of Immunomodulators with Cancer Preventive Agents or Vaccines
Co-Chairs: Altaf Mohammed, Ph.D. and Bryon Johnson, Ph.D.
10:00-10:30 AM

Treatment with Avasimibe, an ACAT Inhibitor, Enhances Tumor Vaccine Efficacy

Bryon Johnson, Ph.D.
Professor, Pediatrics and Microbiology & Immunology
Wisconsin Medical Center

10:30-11:00 AM

Combination Chemo-Immunoprevention of Colon Cancer

Mary (Nora) Disis, M.D.
Professor of Medicine
University of Washington

11:00 AM -11:30 PM

Modulating the Immune Environment for Primary and Secondary Breast Cancer Prevention

Sasha Stanton, M.D., Ph.D.
Assistant Member, Cancer Immunoprevention Laboratory
Providence Cancer Institute

11:30 AM - 12:15 PM Discussion
12:15-1:00 PM BREAK
Session 3**
Immune Checkpoint Inhibitors in Immunoprevention
Co-Chairs: Asad Umar, D.V.M., Ph.D. and Michael Pollak, M.D.
1:00-1:30 PM

Immunoprevention of Cancer in Muir Torre Syndrome with a Checkpoint Inhibitor: What are the Broader Implications of a Successful Case?

Michael Pollak, M.D.
Director, Division of Cancer Prevention
Department of Oncology
McGill University

1:30-2:00 PM

The Spectrum of Opportunities for the Immunoprevention of Carcinomas

Jeffrey Schlom, Ph.D.
Chief, Laboratory of Immunobiology and Biology
Center for Cancer Research, National Cancer Institute

2:00-2:30 PM

Potentiation of Multi-peptide Lung Cancer Vaccines with Immune Checkpoint Antagonist CA-170

Ming You, M.D., Ph.D.
Director of Center for Cancer Prevention
Houston Methodist Cancer Center

2:30-3:00 PM

Using mouse models to discover new immunotherapy approaches for liver cancer

Hao Zhu, M.D.
Professor of Pediatrics and Internal Medicine
Division of Hematology-Oncology
University of Texas Southwestern Medical Center

3:00 PM - 3:45 PM Discussion
3:45 PM - 4:00 PM Final Remarks and Future Plans
Dr. Robert Shoemaker

*The Overviews will be 30 min with 15 minutes for questions. These sessions will be conducted to provide the patient advocacy representatives with an explanation of the science being presented at the sessions and the implications of these findings for their patients.

**Speaker talks will be 20 minutes with 10 minutes for questions.